$1.60 -0.01 (-0.63%)

Ovid Therapeutics Inc. Common Stock (OVID)

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for rare neurological disorders. Founded to address unmet medical needs, the company specializes in leveraging its expertise in neuroscience to bring innovative therapies to patients with conditions such as rare epilepsies and other central nervous system disorders.

🚫 Ovid Therapeutics Inc. Common Stock does not pay dividends

Company News

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc. • N/A • February 27, 2025

Ovid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that its President and COO will present at the upcoming TD Cowen conference. The company is advancing a pipeline of novel small molecule candidates for neurological and neuropsychiatric disorders.

Wall Street Breakfast: The Week Ahead
Seeking Alpha • Wall Street Breakfast • June 30, 2024

Stay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Zacks Investment Research • Zacks Equity Research • June 20, 2024

Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.

Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
Benzinga • Benzinga Insights • May 7, 2024

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bu...